PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19169664-9	2009	Pioglitazone increased mRNA levels for adiponectin receptor 1 and 2 genes (ADIPOR1, ADIPOR2), peroxisome proliferator-activated receptor gamma, coactivator 1 gene (PPARGC1) and multiple genes involved in mitochondrial function and fat oxidation.	Pioglitazone	0-12	PPARG coactivator 1 alpha	Homo sapiens	164-171	
24606795-40	2014	As strategies to induce PGC-1alpha activation, these authors remark the possibility to activate Sirt1 with resveratrol, to use PPAR agonists such as pioglitazone, rosiglitazone, fenofibrate and bezafibrate.	Pioglitazone	149-161	PPARG coactivator 1 alpha	Homo sapiens	24-34	
18324929-0	2008	High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naive type 2 diabetic subjects.	Pioglitazone	130-142	PPARG coactivator 1 alpha	Homo sapiens	56-66	
32114097-14	2020	Postnatal administration of pioglitazone further promoted PGC-1alpha and mitochondrial biogenesis, alleviated hippocampal injury, and improved performance in the behavioral tasks after intrauterine HI.	Pioglitazone	28-40	PPARG coactivator 1 alpha	Homo sapiens	58-68	
15855325-5	2005	Pioglitazone treatment significantly increased mitochondrial copy number and expression of factors involved in mitochondrial biogenesis, including peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha and mitochondrial transcription factor A.	Pioglitazone	0-12	PPARG coactivator 1 alpha	Homo sapiens	147-221	
32114097-16	2020	Promotion of PGC-1alpha by pioglitazone might be a potential treatment for protecting against hippocampal injury and cognitive defects after intrauterine HI.	Pioglitazone	27-39	PPARG coactivator 1 alpha	Homo sapiens	13-23	
31083336-6	2019	Pioglitazone increases the expression of cellular prion protein (PrPC) in CKD-MSCs, which is dependent on the expression levels of proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha).	Pioglitazone	0-12	PPARG coactivator 1 alpha	Homo sapiens	190-200	
31083336-7	2019	Treatment with pioglitazone is found to protect CKD-MSCs against reactive oxygen species generation, aberrant mitochondrial oxidative phosphorylation of complexes I and IV, and aberrant proliferation capacity through the PGC-1alpha-PrPC axis.	Pioglitazone	15-27	PPARG coactivator 1 alpha	Homo sapiens	221-231	
28356907-3	2017	In addition, oral treatment of pioglitazone increased the expression of peroxisome proliferator-activated receptor-gamma coactivator of 1alpha (PGC-1alpha) and increased the number of mitochondria, along with an observed improvement in mitochondrial ultrastructure.	Pioglitazone	31-43	PPARG coactivator 1 alpha	Homo sapiens	144-154	
28356907-8	2017	The results from this study confirm that pioglitazone/2,4-thiazolidinedione is able to activate PGC-1alpha and prevent damage of dopaminergic neurons and restore mitochondria ultrastructure through the regulation of mitochondria function.	Pioglitazone	41-53	PPARG coactivator 1 alpha	Homo sapiens	96-106	
26887289-7	2016	Treatment of subjects with T2DM with pioglitazone increased NPRR in adipose tissue (P <= 0.01) in conjunction with improvements in insulin sensitivity and increases of the thermogenic markers PPARgamma coactivator-1alpha and uncoupling protein 1 (P <= 0.01).	Pioglitazone	37-49	PPARG coactivator 1 alpha	Homo sapiens	195-248	
26210873-8	2015	Finally, the PPAR-gamma agonist pioglitazone increased the expression of PGC-1alpha (a mitochondrial biogenesis master regulator), UCP2 (a mitochondrial protein known to reduce ROS production), and cytochrome oxidase subunit COX1.	Pioglitazone	32-44	PPARG coactivator 1 alpha	Homo sapiens	73-83